Similar Diseases
- ARSACS
- ARSAL
- Autosomal dominant spastic ataxia type 7
- Autosomal recessive spastic ataxia-optic atrophy-dysarthria syndrome
- AD-SPAX
- AR-SPAX
- Autosomal recessive spastic ataxia type 2
- Autosomal dominant spastic ataxia type 1
- Autosomal recessive spastic paraplegia 35
- AFG3L2-related spastic ataxia-myoclonic epilepsy-neuropathy syndrome
Made by DATEXIS (Data Science and Text-based Information Systems) at Beuth University of Applied Sciences Berlin
Deep Learning Technology: Sebastian Arnold, Betty van Aken, Paul Grundmann, Felix A. Gers and Alexander Löser. Learning Contextualized Document Representations for Healthcare Answer Retrieval. The Web Conference 2020 (WWW'20)
Funded by The Federal Ministry for Economic Affairs and Energy; Grant: 01MD19013D, Smart-MD Project, Digital Technologies
Results for Query ‹ ARSACS medication ›
Autosomal recessive spastic ataxia of Charlevoix-Saguenay – Prognosis
Most patients begin to use a wheelchair for movement around age 30-40. Death usually occurs in their 60s, but some have been reported to live longer.
Autosomal recessive spastic ataxia of Charlevoix-Saguenay – Abstract
Autosomal Recessive Spastic Ataxia of the Charlevoix-Saguenay (ARSACS) is a very rare neurodegenerative genetic disorder that primarily affects people from the Saguenay–Lac-Saint-Jean and Charlevoix regions of Quebec or descendants of native settlers in this region. This disorder has also been demonstrated in people from various other countries including India, Turkey, Japan, The Netherlands, Italy, Belgium, France and Spain. The prevalence has been estimated at about 1 in 1900 in Quebec, but it is very rare elsewhere.